Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for North Carolina Only)
This section defines and summarizes several neuromodulation and electrical stimulation modalities (e.g., PNS, peripheral nerve field stimulation, restorative neurostimulation, FES) relevant to pain management and rehabilitation and reviews evidence for functional electrical stimulation (FES) in spinal cord injury and other conditions. It is intended for clinicians evaluating coverage and clinical utility.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for North Carolina Only)
Policy CodePolicy CSNCT0126.10
Change TypeNo material change
Effective DateJun 1, 2026
Next Review Date
Key ActionDocument prior conservative therapies and objective baseline measures when requesting coverage for electrical stimulation therapies.
No material clinical or coverage changes in this revision.
multiplemodalities described
15+studies discussed (FES/SCI)
C–D2evidence quality noted
72%ReActiv8 responder rate
87%
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
Nalu 12‑month responder
Coverage Criteria and Evidence Summaries
inv-01: FES evidence and applicability
Evidence summaries for FES in spinal cord injury and other populations
FES in SCI evidence synopsis: Systematic reviews and RCTs report that FES (including hybrid/assisted cycling and stationary electrically stimulated exercise) can improve respiratory measures (FVC, peak expiratory flow), VO2 peak, muscle mass/strength, bone mineral density and some quality-of-life measures in adults with spinal cord injury; however, studies are small, heterogeneous, and of variable quality, and long-term functional benefits (ambulation) are inconsistently demonstrated.
Hayes HTA ratings vary (C to D2) with limited pediatric evidence and unclear support for implanted-electrode systems.
inv-02: Evidence limitations and general criteria
Evidence-based considerations observed in the reviewed studies and HTAs
General evidence considerations: The evidence base across FES/NMES studies is heterogeneous with many small single-center RCTs, variable device types and protocols, short follow-up, and methodological limitations (risk of bias, lack of blinding), resulting in low-to-moderate certainty and recommendations for larger standardized RCTs.
HTAs (Hayes, others) call for standardized protocols and longer follow-up.
Spinal Cord Injury: Hybrid or stationary FES cycling and FES-assisted exercise show improvements in VO2 peak, muscle mass, and some bone density measures in people with SCI, but ambulatory FES has limited applicability and no consistent superiority for locomotion compared with stationary exercise in randomized comparisons.
Evidence limited by small samples and heterogeneous inclusion criteria.
Cerebral Palsy: FES of ankle dorsiflexors in children with spastic CP increases ankle dorsiflexion angle, strength, selective motor control and gait kinematics, but evidence for activity/participation-level benefits is limited and trials are small with mixed results versus AFOs.
Selection and supervised follow-up are important.
Stroke (foot drop and upper limb): For poststroke foot drop and upper-limb deficits, FES/CCFES and NMES trials report mixed results: some trials show improvements in gait speed, endurance, ankle dorsiflexion and upper-extremity motor scores, whereas larger RCTs have sometimes found no significant 6MWT improvement; overall evidence quality is low-to-moderate and inconsistent.
Benefits may depend on timing (subacute vs chronic) and adjunct supervised therapy.
inv-04: Evidence-based indications and efficacy summary (informational)
Summary of evidence-based findings reported in the document excerpt (not prescriptive coverage criteria):
Stroke - upper limb: CCFES may improve upper-extremity motor outcomes (FMA, Box and Block, AROM) versus cyclic NMES in some trials and meta-analyses, but heterogeneity and risk of bias limit certainty.
Further high-quality RCTs needed.
Stroke - foot drop: FES alone often does not improve gait speed/6MWT versus conventional therapy, though when combined with supervised exercise it can improve gait speed and functional mobility; long-term durability is unclear.
Hayes HTA highlights inconsistent functional/QOL improvements.
MS - foot drop: Low-quality evidence suggests FES provides similar improvements in walking speed and endurance to AFOs and may improve perceived exertion and psychological outcomes, but trials are small and device/protocol heterogeneous.
Hayes rating C for MS foot drop.
inv-05: Evidence summaries (no explicit coverage criteria in excerpt)
Evidence summary relevant to coverage decisions (no explicit policy criteria given in this excerpt):
Orthopedic postoperative applications: RCTs report NMES may reduce early postoperative pain during mobilization, reduce edema, and increase femoral venous peak velocity after THR (potential DVT relevance), but trials are small and short-term.
Clinical relevance and long-term benefit require larger trials.
Rehabilitation and strengthening: Home-based or adjunct NMES/FES programs in ACL reconstruction, amputation rehab, and CP showed maintenance or increases in muscle strength/volume and some functional gains, but sample sizes are small and protocols heterogeneous.
Clinical documentation of protocols and supervised therapy is important.
Poststroke motor and swallowing therapy: Systematic reviews and meta-analyses indicate NMES combined with conventional therapy can improve ADLs and swallowing function after stroke, with greater effects when applied in subacute phases and targeted to upper extremity; evidence certainty varies.
NICE recommends further research and special arrangements for dysphagia use.
inv-06: Evidence summaries by indication
Evidence-supported and conditional scenarios observed in this section:
Post-stroke motor recovery (NMES/CCFES): Meta-analyses indicate NMES can improve ADLs (SMD ~0.41) post stroke; CCFES may offer greater upper-extremity recovery versus cyclic NMES in some trials, with effectiveness influenced by timing (subacute) and severity.
Subgroup effects favor subacute timing and upper-extremity targeting.
Post-stroke dysphagia (NMES): Systematic reviews report NMES plus conventional swallowing therapy can improve swallowing outcomes and QOL, though heterogeneity and variable quality limit definitive conclusions and NICE advises use within governance/research settings.
Consider disease duration and severity in candidate selection.
COPD and respiratory conditions: NMES adjunctive to pulmonary rehabilitation can improve exercise capacity (6MWD), quadriceps strength, and QOL in moderate-to-severe COPD, but certainty is low and protocols vary widely.
Often studied as adjunct to PR rather than replacement therapy.
inv-07: Evidence-based coverage considerations
Evidence summary and implied coverage stance based on available trials and guidelines:
IFT for knee OA: Systematic reviews and meta-analyses report IFT can improve short- and some long-term pain and short-term function in knee OA, but results are heterogeneous and limited by small, variable trials.
Chen et al. and Zeng et al. show mixed findings; larger trials needed.
IFT as adjunct to rehabilitation/postoperative care: Randomized trials in postoperative settings often show mixed or no additional benefit of IFT over sham when added to standard rehabilitation, suggesting limited incremental value in many such contexts.
Trial-level evidence does not consistently support routine adjunctive use.
IFT for nonsurgical MSK pain: Meta-analyses suggest possible short-term pain relief versus placebo, but no clear added benefit when combined with standard care; heterogeneity and low quality limit definitive coverage support.
ACP and NICE guidance recommend cautious or limited use.
inv-08: PENS — evidence summary and coverage stance
Evidence shows short-term/immediate pain benefit in some MSK conditions but limited and inconsistent long-term data; recommendations vary by guideline.
PENS evidence characteristics: Systematic reviews and RCTs of PENS report small-to-moderate immediate reductions in local pressure pain thresholds and pain intensity, with short-term benefit evident in many studies but limited mid- and long-term follow-up and heterogeneity in protocols and anatomical targets.
Meta-analyses show immediate effects not clearly sustained.
Trials report mixed results with small sample sizes and short follow-up; some RCTs showed short-term pain/function improvements while others show no superiority to placebo.
MENS/MET/FSM trial outcomes: Microcurrent (MENS/MET/FSM) trials report reductions in pain and some functional improvements in small RCTs and pilot studies (knee pain, acute knee, elderly muscle function), but other trials (eg, PDN) found no superiority to sham; evidence remains limited and inconsistent.
Larger, blinded RCTs with longer follow-up are needed.
inv-10: PENFS / percutaneous auricular stimulation — pilot evidence
Small randomized pilot data show reduced opioid use and short-term pain after TKA with percutaneous auricular stimulation.
PENFS pilot findings: A randomized, double-masked, sham-controlled pilot following primary TKA found auricular percutaneous stimulation reduced cumulative opioid use and mean daily pain scores over five postoperative days compared with sham, demonstrating feasibility and short-term analgesic benefit.
Small sample and pilot nature limit generalizability; further RCTs warranted.
inv-11: Coverage implications from evidence
Evidence summaries and implications
PENFS for pediatric DGBIs/IBS/CVS: Evidence includes small RCTs and registries indicating short-term symptom improvement in pediatric DGBIs/IBS with IB-Stim/PENFS; Hayes assessment remains no/unclear support and recommendations are for conditional use in refractory pediatric cases.
Registry data show short-term benefit but limited controlled long-term evidence.
PNS for chronic neuropathic/postoperative pain: PNS studies (temporary and permanent systems) show some RCT and observational evidence of clinically meaningful pain reductions and high responder rates in selected refractory populations, but overall certainty is low due to small trials and heterogeneity; careful selection and documentation of prior conservative therapy are advisable.
Ontario Health and Hayes reviews highlight limited but promising RCTs.
inv-12: Indications and evidence quality
ASIPP guidance and systematic review context
ASIPP-supported implantable PNS indication: ASIPP supports implantable PNS in patients with moderate-to-severe chronic pain refractory to two or more conservative treatments and recognizes evidence level III/fair with moderate strength recommendations; temporary 60-day trials are an accepted pathway prior to permanent implant.two or more prior conservative treatments; consider trial up to 60 days
Document prior conservative therapy attempts and trial responses.
Evidence quality summary: Systematic reviews and HTAs characterize overall evidence quality for PNS and related percutaneous systems as low to very low though some RCTs report clinically meaningful responder rates; larger multicenter RCTs are recommended.
Use in carefully selected refractory patients with documentation.
inv-13: PEMF — Covered with limitations / investigational
Coverage stance is mixed and dependent on indication and evidence strength.
PEMF evidence-summary: Systematic reviews and RCTs report inconsistent short-term pain and function benefits in OA and nonspecific LBP with PEMF; trials use varied parameters and short follow-up, producing low certainty for routine pain indications.
Kull et al. and Yang et al. report mixed results; standardized trials needed.
PEMF conditional adjunct use: PEMF has shown adjunctive short-term improvements in small trials when combined with structured exercise or PRP, but added value is uncertain; consider only as adjunct with documented prior conservative therapy and matching trial parameters.
Evidence insufficient to support routine standalone PEMF for pain.
inv-14: PEMF for bone healing — not routinely covered
Explicit exclusion guidance derived from fracture healing reviews and clinical summary.
PEMF for fracture healing: PEMF should not be routinely used to enhance bone healing in acute fractures because randomized trials did not demonstrate consistent benefit across fracture types.
Picelli et al. concluded against routine use for fracture healing.
Restorative neurostimulation may be considered only for patients matching trial entry criteria and after failure of conservative and interventional therapies.
Restorative neurostimulation (ReActiv8) eligibility: Patient meets ALL: (1) mechanical chronic low back pain associated with multifidus dysfunction; (2) ODI between 30 and 60; (3) NRS pain score approximately 6–9; (4) failure of conservative and interventional therapies (including ≥90 days medical management and at least one trial of physical therapy); (5) informed consent and specialist evaluation for implant candidacy.ODI 30-60; NRS 6-9; ≥90 days prior conservative care
Derived from RESTORE and ReActiv8 pivotal trial inclusion criteria.
Considered when ALL of the following are met (evidence-informed criteria derived from pivotal studies):
Restorative neurostimulation candidate criteria: (1) Persistent mechanical CLBP with documented multifidus dysfunction refractory to conservative and interventional therapies; (2) Documentation of prior structured conservative therapy including ≥90 days of medical management and at least one course of physical therapy; (3) Baseline disability and pain severity consistent with trials (eg, ODI ~30–60; NRS 6–9); (4) Specialist assessment confirming implant candidacy and discussion of risks/benefits; (5) Device-specific regulatory indication documented.see node text
Reflects RESTORE and ReActiv8 trial selection and follow-up reporting.
inv-17: Scrambler therapy — evidence and consideration
Evidence summary and when use may be considered:
Scrambler therapy evidence stance: Available RCTs and systematic reviews report small, short-term pain reductions and occasional reduced analgesic use in specific neuropathic conditions, but evidence quality is low-to-very-low and heterogeneity and risk of bias limit confidence; use may be considered in trial contexts or selective refractory cases but is not broadly recommended.
Hayes and guideline bodies advise cautious interpretation and further trials.
Evidence summary and coverage-relevant conclusions for scrambler therapy:
Evidence quality and recommendation: Multiple systematic reviews and guideline assessments characterize scrambler therapy evidence as low to very low quality with inconsistent results; ASCO and other oncology-related groups do not recommend routine use for CIPN or cancer-related pain outside trials.evidence_quality:low/very_low
Coverage outside clinical trials is generally unsupported by guidelines.
inv-19: Scrambler therapy — trial context
When use was studied in trials (context for potential limited coverage):
Typical trial enrollment and regimen: Trials enrolled patients with moderate-to-severe neuropathic pain despite prior therapies and used regimens such as ten 45-minute sessions over 2 weeks; outcomes assessed included pain VAS, QOL, opioid use and mechanistic imaging in some studies.clinical_thresholds:varied
Small sample sizes and short follow-up are common features.
inv-20: PoNS/TLS — overall coverage stance
Translingual stimulation (PoNS/TLS) — evidence and coverage stance:
PoNS evidence summary: Randomized trials combining PoNS with targeted physical therapy report improvements in balance and gait in chronic balance deficits and in MS, but many trials show similar improvements between active and control pulse-frequency groups; evidence is promising yet limited by sample sizes and variability in protocols.evidence_quality:moderate-to-low
Consider device labeling and program adherence documented in trials.
inv-21: Device-specific coverage criteria
Covered when device-specific FDA indication and prerequisite therapies are documented
Restorative neurostimulation (ReActiv8): Device indicated for bilateral stimulation of the L2 medial branch for intractable chronic low back pain associated with multifidus dysfunction; coverage contingent on documentation of multifidus dysfunction and failure of prior therapies including medications and PT as per PMA labeling.document imaging/physiologic evidence of multifidus dysfunction and prior conservative therapy failure
Follow device PMA and document product code QLK.
IB-Stim (PENFS) for pediatric IBS: IB-Stim (De Novo DEN180057) is indicated for functional abdominal pain associated with IBS in patients 11–18 years; coverage requires device De Novo indication and age-appropriate documentation.age 11-18 and device De Novo indication
Document DEN180057 or product code QHH/PZR.
Percutaneous and percutaneous PNS devices:
The available evidence does not support routine coverage of home-based functional electrical stimulation (FES) for rehabilitation following spinal cord injury (SCI). A Hayes evidence brief reviewed limited published data (six abstracts including one small RCT and one single-arm study) and concluded there is insufficient peer-reviewed literature and no clinical position statements to establish benefit for home-based FES in SCI rehabilitation. Trials across neurologic indications generally suffer from small sample sizes, heterogeneous protocols, short follow-up, and variable outcome durability, limiting confidence in long-term functional improvement.
This excerpt does not state explicit procedural exclusions, but health-technology assessments cited in the evidence review identify limitations for certain FES approaches. Notably, HTA reports rate evidence for implanted-electrode FES in chronic stroke as very low quality and found inconsistent functional benefits versus surface-electrode approaches. For a named device (MyndMove), ECRI judged the evidence inconclusive because of limited, high-risk-of-bias studies, indicating current evidence does not firmly support coverage of implanted-electrode rehabilitative FES for chronic stroke.
Device and Product Codes
No explicit codes in this sectionmixed
No codes listed
Device product codes / FDA referencesmixed
GZI
FDA product code referenced for functional electrical stimulation devices (searchable)
IPF
FDA product code referenced for neuromuscular electrical stimulation for muscle rehabilitation
LIH
FDA product code referenced for interferential therapy devices
IB-Stim product code (percutaneous electrical nerve field stimulation, De Novo DEN180057) for pediatric IBS-related abdominal pain
PZR
IB-Stim product code (alternate) referenced
QLK
ReActiv8 product code (PMA) for implantable restorative neurostimulation
Prior Authorization, Documentation, and Authorization Guidance
Prior Authorization
Prior authorization may be required for conditional/limited-evidence indications
Prior authorization may be required for indications with limited or conditional evidence (for example: NMES for dysphagia, IFT for knee osteoarthritis or chronic low back pain, certain PEMF uses, percutaneous/implantable PNS and restorative neurostimulation outside strict trial-based or guideline-supported indications). When PA is required, requests should include clinical justification and supporting high-quality evidence (RCTs, guideline concordance) for the requested indication.
Document prior conservative management and rationale for proceeding to device-based therapy
If implantable PNS is requested, document trial (temporary PNS) duration or rationale if proceeding without a trial per device/society guidance
Note
References-only — no PA listed
This section includes references and evidence summaries; no explicit prior authorization codes or PA process steps are listed here. For operational PA rules and billing codes, refer to payer-specific guidance or the North Carolina-specific UnitedHealthcare Community Plan Medical Policy where applicable.
Conservative Care and Trial Requirements
inv-145: Document prior/concurrent rehabilitation and conservative management when proposing electrical stimulation therapies.
Document prior/concurrent rehabilitation and conservative management when proposing electrical stimulation therapies.
Rehabilitation documentation expectation: Document indication (condition and chronicity), prior and concurrent rehabilitation programs (eg, PT, exercise regimens), objective baseline measures (muscle strength grade, VO2 peak, 6MWD, ODI, NRS), and specifics of the planned stimulation protocol (device, parameters, frequency/duration).document prior/concurrent rehabilitation and objective baselines
Reflects trial commonalities and evidence review recommendations.
inv-146: Consider prior or concurrent trial of AFO/PT where clinically appropriate before FES approval.
Consider prior or concurrent trial of AFO/PT where clinically appropriate before FES approval.
FES comparator expectation:
Treatment Frequency and Typical Protocols
FES therapeutic sessions — Examples from trials
Typical session duration15–40 minutes per supervised session (trial examples)
Typical weekly frequency5 days per week (trial examples)
Typical course length6–8 weeks (trial examples)
Setting and supervisionTherapy delivered by the same therapist or supervised rehabilitation program in trials
Not specified in excerpt; referenced NC policy may include limits.
Policy-specific limitsNot specified in this excerpt; refer to the referenced North Carolina UnitedHealthcare policy for any numeric limits
Imaging and Procedure Guidance
Note
Note
Note
Note
Note
Note
Note
Services Commonly Not Covered / Insufficient Evidence
Not covered: home-based FES for SCI is considered unsupported based on the Hayes evidence brief which found insufficient published peer-reviewed data and no clinical position statements to justify routine coverage. Documentation submitted for this indication is likely to be denied or require additional high-quality evidence demonstrating durable functional benefit.
Not covered: implanted-electrode FES for chronic stroke is not supported by the evidence summarized in HTAs. Hayes concluded the body of evidence for implanted-electrode FES in chronic stroke is of very low quality and did not demonstrate consistent improvements in walking, stroke recovery, or quality of life compared with conservative approaches or surface-electrode FES; ECRI similarly characterized device-specific evidence as inconclusive for some implanted systems.
Not covered: duplicate/mapping placeholder — available evidence and HTA conclusions described above apply (insufficient evidence for home-based FES in SCI and low/very-low-quality evidence for implanted FES in some stroke populations).
Not covered: duplicate/mapping placeholder — see evidence summaries noting limited peer-reviewed evidence and lack of clinical position statements for home-based FES in SCI rehabilitation.
Not covered: duplicate/mapping placeholder — evidence limitations (small trials, heterogeneity, short follow-up) undermine support for routine coverage of rehabilitative FES in the settings described.
Not covered: duplicate/mapping placeholder — submission for coverage of home-based or implanted rehabilitative FES should include RCT-level evidence showing durable functional benefit to be considered.
Clinical Background and Definitions
Neuromodulation and electrical stimulation therapies aim to modulate peripheral or central neural pathways to reduce pain or restore function. Modalities range from noninvasive techniques (for example, scrambler therapy, translingual stimulation, percutaneous auricular stimulation) to minimally invasive or implanted systems (for example, peripheral nerve stimulation, peripheral nerve field stimulation, restorative neurostimulation). Clinical outcomes reported in the literature include measures of pain, muscle strength, aerobic capacity, gait parameters, and quality of life, but evidence strength and generalizability vary by modality and indication.
Percutaneous Electrical Nerve Field Stimulation — definition
DefinitionTargets central pain pathways via the auricular branch of the vagus nerve using alternating frequencies of low-voltage stimulation
Typical applicationPercutaneous leads applied to auricular fields for analgesia (example: NSS-2 Bridge, IB-Stim studies)
Evidence notePublished studies are small and limited; overall quality of evidence weak in many indications
Peripheral Nerve Stimulation (PNS) — definition
Procedural Notes and Frequency / Session Examples
References, Evidence Reviews, and Regulatory Sources
Health technology assessments and evidence reviews cited in this section include named evaluations from ECRI and Hayes as well as systematic reviews and meta-analyses. These HTAs synthesize randomized trials and observational studies across device classes (for example, MyndMove, ReActiv8, IB-Stim, Sprint/Nalu) and provide the primary basis for the document's conclusions about evidence quality and coverage implications.
References are provided for the evidence syntheses and device assessments used in this review; this references list does not include any specific prior-authorization codes or procedural authorizations within the excerpt.
Policy Summary
PayerUnitedHealthcare
PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for North Carolina Only)
Policy CodePolicy CSNCT0126.10
Change TypeNo material change
Effective DateJun 1, 2026
Next Review Date
Key ActionDocument prior conservative therapies and objective baseline measures when requesting coverage for electrical stimulation therapies.
CHF and cardiopulmonary: Leg FES in heart failure/COPD trials can improve peak VO2, 6MWD and QOL versus control, though traditional aerobic training often yields greater gains; evidence limited by small RCTs and heterogeneity.
Trials report physiologic improvements but variable clinical superiority to exercise.
Orthopedic postoperative and NMES adjuncts: NMES as an adjunct to rehab after joint replacement or ACL reconstruction can improve quadriceps strength and some functional outcomes and may reduce early postop pain or edema; evidence is heterogeneous and typically from small single-center trials.
Effect sizes and durability vary across studies.
Evidence limitations: Common limitations across studies include small sample sizes, heterogeneous stimulation parameters, lack of blinding, short follow-up, and variable outcome measures, limiting generalizability and supporting conservative coverage approaches without stronger evidence.
HTAs call for standardized, multicenter RCTs.
CLBP and transcutaneous electrotherapy: Transcutaneous modalities (TENS, IFT, EMS) show mixed results for chronic low back pain; IFT may provide short-term pain/disability reduction in some studies but evidence is heterogeneous and often short-term.effects largely short-term
Guideline recommendations vary; ACP finds insufficient evidence for IFT.
Knee OA and IFT: Network/meta-analyses report modest short- and long-term pain/function improvements with IFT in some trials, but heterogeneity and lack of consistent superiority to exercise limit firm coverage conclusions.
Larger standardized RCTs recommended.
MENS/MCT evidence: Microcurrent evidence is limited and mixed: small RCTs report short-term pain/function gains in selected conditions but overall data are insufficient to support broad coverage without further high-quality trials.
Lawson et al., Iijima & Takahashi, and others document small trials with short follow-up.
Guideline recommendations: Guidelines (ACP, NICE) generally find insufficient evidence to recommend routine IFT/other electrotherapies for many chronic pain conditions, supporting a restrictive coverage stance absent high-quality evidence.
NICE recommends against IFT for knee OA and chronic primary pain in some guidance.
Coverage for percutaneous/implantable PNS devices depends on device regulatory status (510(k)/PMA) and the indication; off-label uses require supporting clinical documentation and demonstration of prior conservative therapy failure.
device 510(k)/PMA clearance and appropriate clinical documentation
Document device product code(s) and indication.
References and evidence assessments are provided for clinical context only
No PA codes or explicit authorization workflows are specified in the references section
Denial Risk
Evidence-related denial risk
Requests lacking high-quality evidence, objective baseline measures, or documentation of prior conservative treatment are at increased risk of denial. Common evidence-related deficiencies include small uncontrolled studies, short follow-up, heterogeneous device protocols, and industry-sponsored trials without independent replication.
Insufficient long-term functional outcome data may trigger denial
Heterogeneity of device parameters and small sample sizes increase denial risk
Denial Risk
Evidence limitations that may trigger denial
Specific evidence limitations that may trigger denial include: very low or low certainty bodies of evidence, lack of randomized or controlled data, inconsistent or negative trial results, and reliance on single-center case series.
Procedures with predominantly retrospective case series or single-arm studies may be noncovered
Short follow-up (< 6–12 months) for durability outcomes can be grounds for denial
Note
Not applicable in this extract — no explicit PA specified
Some excerpts of the source material do not specify authorization requirements or PA triggers. These narrative evidence summaries serve to inform clinical review but may not map directly to operational PA rules.
When no PA is specified, follow local payer/provider contract and medical policy guidance
Use the evidence and documentation expectations in this section to prepare submissions even when no PA code is listed
Denial Risk
Evidence limitations may trigger noncoverage or special arrangement requirements
For certain indications (e.g., NMES for dysphagia), NICE and other reviewers recommend use only with special arrangements, research, or within structured clinical governance; payers may require special arrangement documentation or limit coverage to research settings.
Consider coverage under research/special arrangement when high-quality evidence is lacking
Document IRB/oversight and patient consent when therapy is provided under research arrangements
Denial Risk
Guideline-based denial risk
Guidelines that advise against use (NICE, ACP, others) or recommend limiting certain electrotherapies (e.g., TENS/IFT/PENS for LBP or IFT for knee OA) increase the likelihood that requests will be denied unless clear, trial-quality supporting evidence and guideline-based rationale are provided.
NICE recommendations against offering IFT or PENS for LBP should be addressed in clinical justification
Provide rationale if deviating from guideline recommendations
Denial Risk
PENS for LBP — low evidence
Evidence for PENS in low back pain is limited and of low quality; NICE recommends against PENS for LBP with or without sciatica. Requests for PENS should include strong, indication-specific evidence and clear documentation of prior therapies.
NICE recommends against PENS for LBP due to low-quality evidence
Provide prior conservative therapy attempts and objective outcome measures if requesting PENS
Denial Risk
Evidence insufficiency may trigger denial
Insufficient evidence, inconsistent trial results, and weak or industry-sponsored data for many neuromodulation and electrotherapy modalities may prompt coverage denials when submissions do not meet evidentiary and documentation expectations.
Industry sponsorship without independent corroboration raises uncertainty
Lack of blinded RCTs or long-term durability data increases denial likelihood
Prior Authorization
Conservative therapy prerequisite per ASIPP guidance
ASIPP guidance expects failure of adequate conservative management before considering implantable PNS or restorative neurostimulation. Payers may require documentation of trials of ≥2 conservative treatments and justification that the patient is not a surgical candidate when applicable.
Document at least two prior conservative therapies (e.g., medications, PT, injections) for implantable PNS requests
For restorative neurostimulation, document failure of ≥90 days of medical management and at least one PT attempt
Denial Risk
PEMF — evidence insufficiency
Evidence for PEMF is inconsistent and often insufficient; some RCTs show transient benefits but multiple trials show no added value versus structured exercise. Payers may require a step-through of structured exercise programs before approving PEMF.
Require documentation of structured exercise (PRE) completion and response before PEMF is considered
Consider denying PEMF when only added to exercise without incremental benefit evidence
Restorative neurostimulation (e.g., ReActiv8) has mixed guideline support and limited high-quality independent evidence outside device-sponsored trials; payers may limit coverage to patients meeting strict trial inclusion criteria and documented failure of conservative care.
Restorative neurostimulation requests should include documented multifidus dysfunction and failure of conservative/interventional therapies
Be aware of open-label and manufacturer-sponsored trial limitations when assessing evidence
Denial Risk
Evidence uncertainty may prompt denial
When evidence is uncertain or limited, reviewers may require trial-quality documentation, objective baseline measures, and protocol details; absence of these elements increases the chance of denial.
Lack of objective baseline measures (e.g., ODI, NRS, functional tests) may prompt denial
Absence of treatment protocol specifics (dose, frequency, duration) undermines medical necessity determinations
Denial Risk
Off-label device use may affect coverage
Off-label use of devices (for example, using SCS pulse generators for peripheral nerve field stimulation) can affect coverage decisions; document FDA regulatory status and provide rationale when requesting off-label use.
Identify and document device regulatory pathway (PMA, 510(k), De Novo) and whether proposed use is on-label or off-label
Provide clinical justification and supporting literature for off-label device applications
Note
No authorization requirements specified in this excerpt
No specific authorization requirements are detailed in many of the cited evidence summaries. Providers should consult the payer's operational PA rules and submit complete clinical documentation aligned with the expectations below even when no PA code is provided in these extracts.
Follow payer-specific PA procedures when present
Use the documentation checklist in this section to prepare comprehensive submissions
Documentation Required
Suggested supporting documentation
Suggested supporting documentation to accompany PA or coverage requests: detailed indication and diagnosis, disease chronicity, objective baseline outcome measures (e.g., ODI, NRS, WOMAC, 6MWT), prior conservative treatments and duration, and device-specific information (model, FDA status).
Include dates and duration of prior therapies (PT, medications, injections)
Attach prior imaging or physiologic testing that documents the target pathology
Documentation Required
Suggested clinical documentation elements
Clinical documentation elements expected by reviewers include confirmation of diagnosis (imaging or objective testing when applicable), disease chronicity and severity, prior conservative therapy attempts, and baseline validated outcome scores.
Confirm diagnosis with imaging or standardized diagnostic criteria where applicable (e.g., stroke imaging, Kellgren-Lawrence grading for OA)
Recommended clinical documentation should include indication, prior and concurrent rehabilitation protocols, number and duration of prior interventional therapies, response to conservative measures, and the proposed device/procedure plan with follow-up and outcome measures.
Describe prior rehabilitation program content and adherence
Provide a proposed treatment regimen including session frequency and objective outcome assessment schedule
Documentation Required
Document NMES parameters and indication details
When neuromuscular electrical stimulation (NMES/NMES) or FES is requested, document specific stimulation parameters (device type, electrode/lead placement, frequency, pulse duration, session length, total number of sessions), targeted anatomy, and rationale linking parameters to the intended therapeutic effect.
List device make/model and whether surface, percutaneous, or implantable leads are used
Specify session duration, daily usage expectations, and total planned treatment course
Documentation Required
Support indication, timing, and severity in documentation
Support requests by documenting indication timing, stage/severity of disease, and expected functional goals. For example, note whether stroke is subacute vs chronic, time since index event, and objective thresholds used for trial inclusion in published studies.
Include time-from-event windows (e.g., stroke 1–12 months or >1 year) where trial evidence indicates differential effectiveness
Provide severity thresholds used in trials (e.g., ODI, NRS cutoffs)
Documentation Required
Required clinical documentation
Required clinical documentation for PA or medical necessity review varies by device and indication but generally includes: detailed diagnosis and clinical history, prior/conservative therapy attempts and durations, validated baseline outcome measures, device/procedure plan, provider qualifications, and expected measurable outcomes with timeline.
Document provider training/ability to perform ultrasound-guided percutaneous procedures when applicable
Include objective outcome measures and planned follow-up intervals
Documentation Required
Required clinical documentation for pediatric DGBI/PENFS
For pediatric DGBI or PENFS requests, provide pediatric-specific documentation: prior failed pharmacologic therapies (often multiple agents), baseline symptom indices (API, FDI, NSS), duration of symptoms, prior behavioral or dietary interventions, and parental consent/assent documentation.
Document failure of multiple prior therapies and duration of each
Provide baseline and follow-up pediatric symptom scales (API, NSS, FDI)
Documentation Required
Recommended documentation elements
Recommended documentation elements to support medical necessity include diagnosis (specific neuropathic or nociceptive pain condition), prior conservative treatment attempts and responses, device parameters, prior trial results (if temporary PNS used), baseline validated scores, and anticipated functional goals.
Include opioid usage and attempts at opioid reduction where relevant
Attach prior trial results (e.g., temporary PNS response percentages) when available
Documentation Required
Required clinical documentation for restorative neurostimulation
For restorative neurostimulation requests, required documentation should include confirmed refractory mechanical CLBP with impaired multifidus control, prior failure of conservative care (including ≥90 days of medical management and at least one course of PT), baseline ODI and NRS scores, and a description of why the patient is not a candidate for other surgical interventions.
Provide ODI and NRS baseline values and prior PT documentation
Document imaging or physiologic testing that supports multifidus dysfunction
Documentation Required
Suggested documentation to support medical necessity
Suggested documentation to support medical necessity across modalities: include device regulatory status, citations to RCT-quality evidence when available, detailed conservative therapy history, specific treatment parameters, objective baseline and follow-up measures, and informed consent that discusses evidence limitations.
Cite pivotal trials or guideline recommendations supporting the requested therapy
Provide device product code, FDA pathway (PMA/510(k)/De Novo) and indication status
Documentation Required
Document FDA approval/indication
Document the device's FDA approval/clearance status and labeled indication (PMA, 510(k), De Novo or none). For example, ReActiv8 has PMA approval for a specific multifidus indication; IB-Stim is FDA-cleared for pediatric IBS-related abdominal pain. Off-label uses should be explicitly identified with supporting evidence.
Include product code and approval/clearance date where available
If off-label, provide literature and clinical rationale supporting the proposed use
Note
This section lists supporting literature
This section lists supporting literature, systematic reviews, technology assessments, and guideline conclusions used to inform clinical and coverage determinations. Use these references to substantiate medical necessity and to identify evidence gaps.
Include key HTAs and systematic reviews (Hayes, ECRI, Ontario Health) in the submission
Step-therapy expectations observed in trials: many studies compared electrotherapies to conservative modalities (e.g., ankle-foot orthoses, exercise, PT). Where trials used conservative comparators, documentation that the member completed and failed such conservative options supports escalation to device-based therapy.
Document completion and adherence to comparator conservative therapies used in trials (e.g., AFO, structured PT)
Provide timelines and objective measures showing lack of improvement with conservative care
Step Therapy
Step-through conservative therapy before electrotherapy
Before device-based electrotherapy (PEMF, NMES, PENS, PNS), expect step-through of structured conservative therapy such as supervised exercise, multidisciplinary rehabilitation, bracing, or proven adjuncts; document completion and response to those programs.
Require documentation of supervised exercise program completion when indicated
Include rehabilitation program details and objective outcome measures
Step Therapy
Prior conservative therapy expected
Prior conservative therapy is generally expected before device-based interventions. Provide dates, duration, and outcomes of medical management, physical therapy, bracing, injections, and other noninvasive treatments attempted and their responses.
Document at least 90 days of medical management for certain restorative neurostimulation indications
List specific pharmacologic, rehabilitative, and interventional therapies tried and the clinical response
Prior Authorization
Trial / step requirement for implantable PNS
For implantable PNS systems, some professional guidance (ASIPP) and trial designs support a prior temporary PNS trial (e.g., 60 days) before permanent implantation; policies may require documentation of a successful short-term PNS trial or provide rationale for proceeding without one.
Document trial length, response criteria (e.g., ≥50% pain relief), and objective measures from the temporary PNS period
If no trial performed, include rationale per clinical guidelines or patient-specific contraindications
Step Therapy
Require trial of structured exercise before PEMF
Some PEMF studies show no added benefit when combined with progressive resistance exercise (PRE); payers may require completion of a structured and documented exercise program prior to approving PEMF for knee OA or CLBP.
Require documentation of PRE program completion and lack of sufficient response before PEMF consideration
Provide objective functional outcomes from PRE (e.g., walking speed, chair-stand)
Step Therapy
Conservative therapy required before implant
Across neuromodulation modalities, clinical trials and guidance consistently emphasize the need for documented failure of conventional medical management (pharmacologic therapies, PT, other standard care) before considering device-based implants or long-course electrotherapies.
Document pharmacologic trials, PT adherence, and interventional therapy history
Explain why conventional options are inadequate or contraindicated
Step Therapy
Conservative therapy before neuromodulation
Clinical trials of neuromodulation often required prior or concurrent use of standard medical therapies (e.g., WHO analgesic ladder, gabapentin) and documented rehabilitation attempts. Requests should mirror trial inclusion criteria when seeking coverage.
Include medication history and rehabilitation attempts consistent with trial protocols
Provide evidence of medical optimization prior to device consideration
When FES is proposed for foot drop or gait impairment, document prior trials of conservative measures (eg, ankle-foot orthosis, supervised physical therapy) or rationale for alternative selection; trials often compared FES with AFO or conventional PT.
Documentation of AFO/PT trial or reason for FES as alternative is expected based on trial comparators.
inv-147: (group mapping placeholder) — related conservative-treatment references
Conservative therapy comparator note: Many trials evaluated FES/NMES as an adjunct to conventional therapy rather than as standalone first-line treatment; therefore documentation should clarify whether FES is adjunctive to an ongoing rehabilitation program.
Evidence commonly uses combined therapy vs conventional therapy alone.
inv-148: Document prior rehabilitation interventions when applicable
Document prior rehabilitation interventions when applicable
Prior rehabilitation duration examples: Trials used varied rehabilitation durations (examples range from 4 to 48 weeks, with many common courses of 4–12 weeks); document prior supervised rehabilitation timing, intensity, and adherence when submitting for stimulation therapies.
Provide specifics of prior programs to align with trial comparators.
inv-149: Trial of appropriate conservative care prior to NMES/IFT is expected given limited/additional benefit evidence
Trial of appropriate conservative care prior to NMES/IFT is expected given limited/additional benefit evidence
Conservative-first expectation for NMES/IFT: Document prior trial of guideline-recommended conservative care (exercise, structured rehab, bracing where indicated) before considering NMES or IFT, as evidence of additional benefit over conservative care is mixed.
NICE and ACP guidance support conservative-first approaches.
inv-150: Document prior trial of guideline-recommended conservative care before considering IFT/MENS.
Document prior trial of guideline-recommended conservative care before considering IFT/MENS.
IFT/MENS conservative requirement: Before considering IFT or microcurrent therapies for chronic pain conditions, document prior guideline-recommended nonpharmacologic therapies (eg, exercise, multidisciplinary rehabilitation) given guideline statements that evidence is insufficient to support routine use without such attempts.
NICE recommends against offering IFT for some indications; ACP finds insufficient evidence.
inv-151: Document prior or concurrent rehabilitation when requesting PENS or adjuvant microcurrent therapy
Document prior or concurrent rehabilitation when requesting PENS or adjuvant microcurrent therapy
PENS/microcurrent rehabilitation requirement: Studies typically included PENS or microcurrent as adjuncts to structured rehabilitation; document prior or concurrent rehabilitation and note that minimum rehabilitation periods in some series ranged from 30 to 90 days.minimum rehabilitation 30–90 days when applicable
Provide rehabilitation details and session counts.
inv-152: Documented failure of conservative therapies (medications, PT, other standard care) is expected for refractory indications.
Documented failure of conservative therapies (medications, PT, other standard care) is expected for refractory indications.
Refractory indication requirement: For refractory chronic pain or postoperative indications being considered for PNS/PENFS, document failure of multiple prior conservative therapies (eg, medications, PT), consistent with trial populations that enrolled refractory patients.
ASIPP guidance suggests two or more prior conservative treatments for implantable PNS candidates.
inv-153: Document prior conservative therapy attempts and responses; consider temporary PNS trial (up to 60 days) prior to permanent implant per guidance.
Document prior conservative therapy attempts and responses; consider temporary PNS trial (up to 60 days) prior to permanent implant per guidance.
Temporary PNS trial consideration: For implantable PNS, document at least two prior conservative treatments and consider a documented temporary PNS trial (eg, up to 60 days) with objective outcome measures before permanent implantation, per ASIPP and HTA guidance.temporary trial up to 60 days; two or more prior conservative therapies
Document trial duration, baseline and post-trial pain/function scores.
inv-154: Require documentation of prior structured conservative therapy (physical therapy, exercise programs) and prior interventional therapy attempts before restorative neurostimulation; consider trial of exercise/PRE prior to PEMF for knee OA.
Require documentation of prior structured conservative therapy (physical therapy, exercise programs) and prior interventional therapy attempts before restorative neurostimulation; consider trial of exercise/PRE prior to PEMF for knee OA.
Structured-conservative prerequisite: Before restorative neurostimulation or adjunctive PEMF for knee OA, document prior structured conservative therapy (eg, supervised PT, progressive resistance exercise) and any prior interventional therapy attempts; for knee OA consider trial of PRE before PEMF given comparable outcomes in some trials.
inv-155: Documentation of prior conservative management failure before considering implantable restorative neurostimulation
Documentation of prior conservative management failure before considering implantable restorative neurostimulation
≥90 days prior conservative management: Document failure of ≥90 days of medical management and at least one course of physical therapy prior to consideration of implantable restorative neurostimulation, reflecting inclusion criteria used in pivotal trials.≥90 days prior medical management; at least one PT course
Baseline ODI and NRS consistent with trial inclusion should be recorded.
inv-156: Document prior conservative medication and therapies and inadequate response before considering neuromodulation.
Document prior conservative medication and therapies and inadequate response before considering neuromodulation.
Medication and therapy failure documentation: For neuromodulation (eg, scrambler, PNS, PoNS), document prior use and inadequate response to standard medical therapies (eg, WHO analgesic ladder agents, gabapentin) and nonpharmacologic therapies consistent with trial populations.
Include baseline pain scores and description of prior therapy regimens and durations.
inv-157: Document prior failure of conservative therapies before implant consideration
Document prior failure of conservative therapies before implant consideration
Implant candidacy conservative prerequisite: Prior to implant consideration for restorative neurostimulation or implantable PNS, providers should document failure of conservative therapies (medications and PT) and evidence supporting device-specific indication per regulatory labeling.
Device PMA/510(k)/De Novo status and indication should be included in documentation.
Trial variability
Study protocols and duration varied by indication and device
DocumentationPrior authorization language in NC policy referenced for procedure/code-level rules
NMES — study-specific regimens
Example regimensStudy-specific regimens such as 20 sessions over 5 days or daily sessions for multiple weeks
Postoperative useShort intensive courses (e.g., 20 sessions over 5 days) reported in enhanced recovery after THR trials
Swallowing/dysphagia coursesNMES courses ranged from 2 to 12 weeks in dysphagia RCTs/meta-analyses
CCFES/NMES — protocols in trials varied
CCFES/CCFES+NMES frequency examplesProtocols varied: examples include 10 sessions/week plus lab visits over 12 weeks
Short daily sessions example20-minute sessions 5x/week for 3 weeks reported in upper-extremity trials
Protocol heterogeneityTrial protocols varied by phase of stroke recovery and study design—no single standardized regimen
IFT/MENS sessions (trial protocols varied)
Session duration examplesTrial protocols commonly used 20–30 minute sessions multiple times per week
Course length variabilitySome RCTs used daily or twice-daily short courses; others delivered sessions across several weeks with no uniform limit
No uniform limit establishedHeterogeneous protocols and inconsistent evidence; no standardized per-course/session cap in excerpt
PENS / PENFS — example study protocols
ACL reconstruction RCT exampleTwo PENS sessions combined with a 12-week rehabilitation program (ultrasound-guided femoral PENS)
Auricular PENFS exampleSingle continuous 5-day device use after TKA (NSS-2 Bridge) in a randomized pilot
No standardized frequency limitExample protocols ranged from single 5-day device application to two targeted sessions; no uniform frequency limit established in excerpt
No explicit frequency limits provided in this section
General statementNo explicit frequency limits are provided in this section of the document for many modalities
Evidence heterogeneity impactLack of standardized protocols across trials means frequency limits are not specified
Implication for authorizationPrior authorization should request trial-specific regimen details when relevant
Frequency limits — not specified in excerpt
Excerpt findingFrequency limits are not specified in this excerpt for many modalities
Protocol reportingTrials reported variable session counts and durations rather than standardized yearly caps
RecommendationDocument the number and timing of sessions in authorization requests to reflect trial regimens
PEMF therapy — Treatment regimens varied in trials
Session frequency rangeTrials used 2–7 sessions per week (examples across LBP and OA studies)
Session duration rangeSessions typically 10–30 minutes per session in reported RCTs
Course variability and heterogeneitySome trials used daily or five-times-weekly schedules for 4–12 weeks; protocols varied widely across indications—no single standard
Programming regimenDevice activation typically prescribed as two daily sessions (eg, 30 minutes twice daily)
Not a per-year limitReActiv8 is a programmable, ongoing therapy schedule rather than a fixed per‑year session cap
Follow labelingFollow device labeling and trial protocols for recommended use and scheduling
Scrambler therapy — Typical trial course
Typical course lengthTen sessions delivered over 2 weeks (e.g., ten 45-minute sessions) in many RCTs
Session duration exampleApproximately 45 minutes per session in typical scrambler protocols
Indication contextUsed mainly for neuropathic pain syndromes in trials with short-term follow-up
Translingual stimulation (PoNS) plus PT — program ranges
Program duration rangePrograms ranged from 5 to 14 weeks in trials when paired with physical therapy
Daily use examplesDaily or twice-daily use paired with PT was reported in trial protocols
Course-context recommendationUse was studied as part of combined PT programs; document PT regimen and device dosing when requesting coverage
ReActiv8 implant — follow device labeling
Implant frequency guidanceFollow device labeling for implantation frequency and candidacy (ReActiv8 PMA indication)
Device-specific requirementsImplantation and follow-up per manufacturer labeling and trial inclusion criteria
DocumentationDocument device regulatory status and indication in authorization requests
Note
Note
Note
Note
Note
Note
Note
Not covered: duplicate/mapping placeholder — current HTAs and evidence briefs do not provide sufficient high-quality data to support routine coverage for these indications.
Not covered: duplicate/mapping placeholder — claims for home-based FES for SCI or implanted FES for chronic stroke are at high risk for denial absent substantive new evidence.
Not covered: duplicate/mapping placeholder — reviewers should reference the Hayes and ECRI assessments when evaluating requests for these FES modalities.
Not covered: duplicate/mapping placeholder — in the absence of consistent trial evidence and guideline endorsement, routine coverage is not supported.
Not covered: duplicate/mapping placeholder — documentation of device regulatory status or trial enrollment does not substitute for robust clinical-effectiveness data.
Not covered: duplicate/mapping placeholder — requests for these applications should be evaluated against the cited HTAs and may be denied without stronger evidence.
Not covered: duplicate/mapping placeholder — current evidence summaries identify insufficient data to support home-based FES for SCI or implanted rehabilitative FES for chronic stroke.
Not covered: duplicate/mapping placeholder — consider referral to research protocols or coverage with evidence development for these indications only where applicable.
Not covered: duplicate/mapping placeholder — payer medical necessity reviewers should require RCT-level evidence with standardized protocols and longer follow-up before approving routine coverage.
DefinitionElectrode(s) implanted or placed near a peripheral nerve to deliver electrical impulses that disrupt transmission of pain signals
Device examplesSystems include StimRouter, SPRINT, and other percutaneous or implantable PNS systems
Evidence summaryEvidence includes small RCTs, case series, and registries with mixed quality; further large RCTs needed
Peripheral Nerve Field Stimulation — definition
DefinitionImplantation of electrode arrays in subcutaneous tissue of the painful area when the painful field is not well defined
Regulatory noteNo devices specifically approved for PNFS; studies often used SCS implantable generators off-label
EvidenceEvidence limited to small trials and case studies; robust comparative trials lacking
Restorative Neurostimulation — definition
DefinitionMinimally invasive stimulation of the multifidus muscle via leads near the medial branch of the dorsal ramus to rehabilitate neuromuscular control
Device exampleReActiv8 Implantable Neurostimulation System
Indication contextIntended for mechanical CLBP associated with multifidus dysfunction after failure of conservative therapy
DefinitionElectrical stimulation used to activate muscles to improve strength, aerobic capacity, respiratory function, gait, or quality of life in neurologic and MSK conditions
Common indicationsSCI, stroke, CP, MS, CHF, and postoperative muscle rehabilitation
Evidence characteristicsTrials show heterogeneous protocols and mixed long-term functional outcomes; further high-quality RCTs needed
Assistive FES vs Rehabilitative FES — definition
Assistive vs RehabilitativeAssistive FES substitutes for lost motor control during function (e.g., foot drop correction); rehabilitative FES aims for long-term motor recovery via therapy
Evidence distinctionEvidence quality and outcomes differ between assistive and rehabilitative FES approaches
ImplicationSelection and documentation should indicate intended use (assistive vs rehabilitative)
DefinitionElectrical stimulation applied to produce functional movements (e.g., dorsiflexion for foot drop, upper limb grasp) often combined with therapy
Use casesUsed in gait, respiratory, and upper-extremity rehabilitation trials
Evidence noteEffectiveness varies by condition, timing, and protocol heterogeneity
EvidenceSeveral systematic reviews/meta-analyses support adjunctive benefits but note low certainty and protocol heterogeneity
CCFES — definition
DefinitionContralaterally controlled FES (CCFES) where voluntary movement of the nonparetic limb controls stimulation of the paretic side
Intended effectAugments motor retraining by linking contralateral voluntary motion to stimulated movement in the paretic limb
Trial evidenceRCTs report improved upper-extremity motor outcomes vs cNMES in some studies
CCFES — definition (alternate)
Alternate descriptionCCFES: stimulation of the paretic limb controlled by movements of the nonparetic limb; studied vs conventional NMES for poststroke upper limb rehab
Protocol examplesHome-based and lab sessions combined over 12 weeks with up to 10 sessions/week reported
Evidence noteSome trials show improved dexterity (Box and Block) and motor scores in selected subgroups
IFT — definition
DefinitionInterferential therapy (IFT) is a medium-frequency transcutaneous electrical stimulation modality evaluated for MSK pain and OA
Typical deliveryMedium-frequency currents applied via surface electrodes; session durations and schedules vary by trial
Evidence summarySystematic reviews show mixed short-term pain/function benefits with heterogeneity across studies
Interferential therapy (IFT) — definition
Alternate definitionA medium-frequency electrical stimulation modality evaluated for postoperative recovery and musculoskeletal conditions
Trial findingsSome RCTs found no added benefit over sham when added to rehabilitation; knee OA meta-analyses show modest effects
Guideline contextNICE recommends against offering IFT for knee OA, chronic primary pain, and LBP in some guidance contexts
PENFS / Percutaneous Electrical Nerve Field Stimulation — definition
DefinitionPercutaneous auricular neuromodulation using small percutaneous leads (e.g., NSS-2 Bridge, IB-Stim) to stimulate cranial/auricular fields for postoperative or visceral pain
Typical applicationUsed in pediatric IBS, postoperative analgesia, and TKA pilot trials
Evidence notePilot RCTs show short-term opioid/pain reductions after TKA; overall evidence weak and limited
DefinitionPercutaneous peripheral nerve stimulation: temporary or implantable leads placed adjacent to peripheral nerves delivering electrical stimulation for chronic peripheral or postsurgical pain
Typical trial durationsExamples include 60-day temporary therapies and leads left in situ for up to 8 weeks in trials
Reported outcomesTrials report high responder rates (eg, 60% ≥50% pain relief in TKA PNS); overall evidence quality varies
Peripheral nerve field stimulation (PNFS) — definition
DefinitionPeripheral nerve field stimulation (PNFS) involves subcutaneous leads to stimulate a field over a painful region when single nerve targets are inadequate
Regulatory noteNo devices specifically approved for PNFS; studies often use SCS generators off-label
EvidenceLimited to small trials and case reports; more robust trials needed
DefinitionTemporary or implantable percutaneous leads placed adjacent to named peripheral nerves to deliver electrical stimulation for chronic peripheral or postoperative pain
Examples of targetsFemoral, sciatic, saphenous, and medial branch targets described in studies
Treatment patternsProtocols vary widely: daily hours of use (eg, 6–12 hours/day for 60 days) or continuous in situ lead durations reported
PEMF therapy — definition
DefinitionNoninvasive application of pulsed electromagnetic fields with varying frequencies (e.g., 3–50 Hz) and intensities delivered in sessions typically 10–30 minutes
Session and frequency variabilityTrials used 2–7 sessions/week and durations from 10 minutes up to 30 minutes per session
Evidence summarySystematic reviews report mixed short-term pain/function benefits with heterogenous protocols and short follow-up
Duplicate device noteReActiv8 is an implantable neuromuscular stimulator indicated for multifidus-targeted stimulation in refractory mechanical CLBP
EvidenceRESTORE and other trials show clinically meaningful improvements when trial criteria met, but open-label designs and manufacturer sponsorship noted
Implant follow-upLong-term follow-up reports sustained benefit in selected cohorts up to 4 years in single-arm studies
Scrambler therapy — definition
DefinitionNoninvasive electrical neuromodulation delivered in multiple sessions over consecutive days intended to modulate neuropathic pain
Typical protocolMultiple daily sessions over 1–2 weeks (eg, ten 45-minute sessions over 2 weeks) in many RCTs
Evidence summarySystematic reviews indicate insufficient high-quality evidence and heterogeneous study designs; further trials recommended
DefinitionImplanted neuromuscular stimulators (eg, ReActiv8) indicated to stimulate specific medial branch targets to aid management of intractable CLBP associated with multifidus dysfunction
Regulatory noteReActiv8 received PMA and labeling specifies patient selection and device programming
Clinical implicationCoverage and implantation should follow device labeling and documented prior conservative therapy failure
Peripheral nerve field stimulation — definition
DefinitionStimulation of peripheral/subcutaneous fields using implanted leads when pain maps to a region rather than a single nerve
Regulatory noteNo devices specifically approved for PNFS; use often relies on off-label SCS generators
EvidenceLimited trial evidence; more controlled studies needed
Health technology assessment / Evidence review — named assessments
Assessment sourcesHealth technology assessments and evidence reviews cited include ECRI, Hayes, and Ontario Health
Use of HTAsHTAs inform evidence strength, device assessments, and regulatory considerations referenced across the document
ImplicationRefer to named HTAs for detailed device-specific evidence summaries and recommendations